Clinical Trial

A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists

Study acronym: FINALITY-HF
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-09-11; most recent amendment 2026-07-08.
Status change: Not Yet Recruiting → Recruiting 2025-01-15
Trial Details
NCT Number NCT06033950
Lead Sponsor Colorado Prevention Center
Collaborators: St. Luke's Hospital, Kansas City, Missouri, Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Conditions Heart Failure
Enrollment 2,600 participants
Start Date 2024-08-20
Primary Completion 2026-08 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-10